Lipitor sales 2020

Annual Sales of Lipitor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Sales projections: What is the expected Lipitor revenue path over 5-10 years under generic price compression? Featured snippet answer: Lipitor sales over the next decade are expected to track a declining brand share multiplied by net price that continues to compress toward generic equivalents, while total atorvastatin class demand is broadly … Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Humira, introduced by AbbVie in 2003, is expected to remain the drug with the highest lifetime revenue through 2024. Keytruda follows with a lifetime revenue of 213 billion U.S. dollars. RELATED: The top 20 drugs by global sales in 2019 As biosims and generics hit sales of several of the industry's top drugs, Remicade's 2020 performance shows that entrenched biologics can keep … Worldwide revenue of Pfizer's Lipitor from 2003 to 2019 (in million U.S. dollars) Pfizer's Lipitor revenue worldwide 2003-2019 Ask AI Premium | Feb 28, 2020 Lipitor (atorvastatin) was discovered at Parke-Davis and launched in 1997, the fifth statin on the market. It became the world's best-selling drug, with sales peaking at US$12.9 billion in 2006, until Humira overtook its lifetime sales in 2020. What were Lipitor (atorvastatin) sales by year? I don't have the year-by-year Lipitor sales figures in the information provided here, so I can't produce an accurate table "by year" without pulling from a specific sales dataset or filings source. Historical largest selling pharmaceuticals 2020-2024 2024 The top ten best-selling pharmaceuticals of 2024. Sales in billion USD. [2] MyMinfin is your secure online portal to manage your tax and financial matters with the Belgian Federal Public Service Finance. Counting up 25 years' worth of sales, Pfizer's Lipitor remains the U.S.' best-selling drug over the past two and a half decades, but AbbVie's Humira will soon catch up. (Pixabay/CC0) Take a look … LIPITOR Market size is expected to reach USD 937.7 Mn by 2033 from USD 1,386.6 Mn in 2026, exhibiting a CAGR of -5.2% during the forecast period 2026-2033 Oroscopo del Giorno Mercoledì 12 Agosto 2026 di Lucia Arena – Il segno del giorno: Toro – Leggi qui il tuo oroscopo del giorno. The Lipitor Market, valued at USD 1.38B in 2026, is projected to reach USD 2.03B by 2034, growing at a 4.9% CAGR. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … The hypercholesterolemia segment held the largest share of the global Atorvastatin Calcium market in 2025, capturing 45.9% of total revenue. The increasing prevalence of elevated cholesterol levels, driven by sedentary lifestyles, obesity, unhealthy dietary habits, and aging populations, has significantly contributed to the segment's leadership. Internet communications tools Document preparation Computing industry Computing standards, RFCs and guidelines Computer crime Language types Security and privacy Computational complexity and cryptography Cryptography Data encryption Multimedia information systems Business process management Enterprise computing Format and notation Government technology policy Human computer interaction (HCI … LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … Explore the best-selling drugs US pharma produced over 25 years, from Lipitor to Humira, and what clinical research made each blockbuster possible. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … The Global LIPITOR Market is estimated to be valued at USD 1,386.6 Mn in 2025 and is expected to reach USD 937.7 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -5.4% from 2025 to 2032. The global LIPITOR market, once a dominant force in the pharmaceutical industry, is now experiencing slow and steady growth, driven by the ongoing demand for atorvastatin calcium, a widely … Lipitor was approved by the government in 1997, and while under patent protection it was the highest-selling drug of all time with worldwide sales of more than US$12 billion a year. Clearly this analysis is distorted to some extent by the earlier launch date of Lipitor (in 1996). However, if we look at cumulative sales during the first 10 years of availability, Lipitor still … Learn about LIPITOR® (atorvastatin calcium), a prescription medication that may help your condition. Read the Important Safety Information. BOSTON (MarketWatch) — Pfizer's cholesterol-lowering drug Lipitor is still the top-selling branded prescription drug in the world, according to IMS Health, a major compiler of sales data for the … Pfizer is once again confronting a major patent cliff, similar to the one it faced in the early 2010s when it lost exclusivity on several high-revenue drugs including Lipitor, Protonix, and Geodon. During that period, Lipitor's annual sales declined significantly from a peak of $12.9 billion following the entry of… In the time of patent loss, between 2011 and 2012, Pfizer's revenue through Lipitor declined by some 60 percent. But both Humira and Lipitor are still the leading drugs by lifetime sales worldwide. Also presented below is a comparison of full-year 2019 results excluding the revenue contribution from the Consumer Healthcare (1) segment to Pfizer's 2020 Total Company (4) financial guidance for revenues and Adjusted diluted EPS (3) at 2019 foreign exchange rates and at mid-January 2020 foreign exchange rates. In fact, at the current rate, Humira could easily dethrone Lipitor next year. After all, it brought in nearly $20 billion worldwide last year, and U.S. sales growth is softening the EU biosimilars … So, this year, it has snatched the crown for the industry's most successful drug from Lipitor (atorvastatin), a cholesterol-lowering drug that racked up ~$160 billion in full-year sales in 23 … A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 ½ years. FDA provides a searchable list of recalled products. Drug recalls are actions taken by a firm to remove a product from the market. Lipitor, Protonix, and the Pfizer Product Line Between 2010 and 2012, drugs that make up 42% of Pfizer's pharmaceutical revenue, including Lipitor, Protonix (pantoprazole) and Geodon (ziprasidone), will all have lost patent protection. With a $93 million settlement, Pfizer can wash its hands of more than a decade's worth of antitrust litigation over the once-lucrative cholesterol med Lipitor.